Sustained EKR inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy

Article ID	Journal	Published Year	Pages	File Type
10800575	Biochimica et Biophysica Acta (BBA) - General Subjects	2013	12 Pages	PDF

Abstract

âº We here evaluate PDT as neoadjuvant to EGFR targeting therapeutics. âº Cetuximab, Erlotinib and Tyrphostin were combined with PDT in two cancer cell lines. âº Synergy was observed when the EGFR targeting drug exerted prolonged ERK inhibition. âº Synergistic cytotoxicity was linked to synergistic ERK inhibition.

Keywords

EGFR 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan TKI mAb ERK PDT MTT Monoclonal antibody Erlotinib Photodynamic therapy Cetuximab Photodynamic Tyrosine kinase inhibitor extracellular signal-regulated kinase Extracellular signal-regulated kinase (ERK)Epidermal growth factor receptor Epidermal growth factor receptor (EGFR)